Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.53 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 13/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11968483 | 0.87 | MAP4K1 (0.57) | ABL1MAP4K1AAK1KITNTRK1 | |
| SCHEMBL5060766 | 0.84 | FGFR2 (0.41) | ABL1MAP4K1AAK1KITNTRK1 | |
| SCHEMBL5060867 | 0.83 | MAP4K1 (0.60) | ABL1MAP4K1AAK1KITNTRK1 | |
| SCHEMBL11968481 | 0.82 | AAK1 (0.54) | ABL1MAP4K1AAK1KITNTRK1 | |
| SCHEMBL11968515 | 0.81 | ABL1 (0.64) | ABL1MAP4K1AAK1KITNEK1 | |
| SCHEMBL1516639 | 0.81 | ABL1 (0.62) | ABL1MAP4K1AAK1KITNTRK1 | |
| SCHEMBL8321166 | 0.80 | KIT (0.73) | ABL1MAP4K1AAK1KITDYRK1A | |
| SCHEMBL12763542 | 0.80 | KIT (0.74) | ABL1MAP4K1AAK1KITNTRK1 | |
| SCHEMBL12762885 | 0.79 | ABL1 (0.66) | ABL1MAP4K1AAK1KITDYRK1A | |
| SCHEMBL11968506 | 0.79 | ABL1 (0.50) | ABL1MAP4K1AAK1KITNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242280-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242280-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008124848-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | ABL1 110/4885MAP4K1 17/4885AAK1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.